Adolescent; Adult; Anticonvulsants/blood/pharmacokinetics; Contraceptives, Oral/pharmacology; Drug Interactions; Epilepsy/blood/drug therapy/physiopathology; Female; Humans; Kinetics; Menopause/blood/physiology; Menstrual Cycle/blood/physiology; Middle Aged; Prospective Studies; Time Factors; Triazines/blood/pharmacokinetics; Young Adult
Abstract :
[en] OBJECTIVE: We prospectively evaluated the fluctuation of lamotrigine (LTG) clearance during the menstrual cycle. We also assessed the effect of postmenopausal status and investigated in detail the effect of oral contraceptives (OCs) on LTG clearance. METHODS: Three groups of women with epilepsy using LTG monotherapy were evaluated. Women in the first group (n = 7) had a regular cycle and did not use OCs; the second group used a 1-phase combined OC (n = 7), and the third group (n = 7) was postmenopausal. Two menstrual cycles or at least 2 months (postmenopausal women) were assessed, monitoring LTG levels every other day. RESULTS: The mean apparent LTG clearance in women of reproductive age not using OCs was 49 (SD 22.6, range 20.4-83.5) L/24 hours. No significant effect of endogenous hormones on LTG clearance was found. In women using OCs, the mean LTG clearance was 126 (SD 60.2, range 44.3-205) L/24 hours. There was an increase in LTG levels during the pill-free week, with maximum levels 54% (range 29%-129%) higher than baseline levels. LTG levels decreased to the baseline value within a mean of 8 days of starting OC use (SD 3.7, range 2.5-16.5). In the postmenopausal women, the mean clearance was 82 (SD 38.4, range 35.9-125) L/24 hours. CONCLUSIONS: We observed a higher mean lamotrigine (LTG) clearance in postmenopausal women compared with young women not using oral contraceptives (OCs) and confirmed that OC use may have a strong effect on LTG clearance. There was no significant fluctuation of LTG clearance during the menstrual cycle.
Disciplines :
Genetics & genetic processes
Author, co-author :
Wegner, Ilse
Edelbroek, Peter M.
BULK, Saskia ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Lindhout, Dick
Language :
English
Title :
Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives.
Publication date :
2009
Journal title :
Neurology
ISSN :
0028-3878
eISSN :
1526-632X
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001;47:151-154.
Sabers A, Ö hman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-571.
Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007;48: 484-489.
Öhman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000;41:709-713.
Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology 2002; 59:251-255.
Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004;62:292-295.
de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:571-573.
Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009;72:911-914.
Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006;34:1055-1062.
Dickins M, Chen C. Lamotrigine: Chemistry, biotransfor-mation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:370-379.
Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids: an update. Clin Pharmacokinet 1991;20:15-37.
Vermeij TAC, Edelbroek PM. Robust isocratic high performance liquid chromatographic method for simultaneous determination of 7 antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chrom B 2007;857:40-46.
Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006;61:191-199.
Stodieck SRG, Schwenkhagen A. Lamotrigine plasma levels and combined monophasic oral contraceptives (COC) or a contraceptive vaginal ring: a prospective evaluation in 30 women. Epilepsia 2004;45(suppl 7):187. Abstract.
Schwenkhagen AM, Stodieck SRG. Interaction between lamotrigine and a progestin-only contraceptive pill containing desogestrel 75ug. Epilepsia 2004;45(suppl 7):144. Abstract.
Reimers A, Brodtkorb E, Helde G. Ethinylestradiol, but not gestagens, reduces lamotrigine serum concentrations. Epilepsia 2004;45(suppl 7):143. Abstract.
Speroff L, Fritz MA. Regulation of the menstrual cycle. In: Speroff L, Fritz MA. Clinical Gynaecologic Endocrinology and Infertility, 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2004:187-232.
Reimers A, Brodtkorb E, Helde G, Spigset O. Lamotrigine serum concentrations throughout the menstrual cycle: a study of 2 cases. Clin Neuropharmacol 2006;29:160-162.
Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991;51:347-369.
Battino D, Croci D, Granata T, Mamoli D, Messina S, Perucca E. Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. Ther Drug Monit 2001;23:217-222.
Reinsberger C, Dorn T, Krämer G. Smoking reduces serum levels of lamotrigine. Seizure 2008;17:651-653.
